BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 36970720)

  • 1. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma
    Glencer AC; Miller PN; Greenwood H; Maldonado Rodas CK; Freimanis R; Basu A; Mukhtar RA; Brabham C; Kim P; Hwang ES; Rosenbluth JM; Hirst GL; Campbell MJ; Borowsky AD; Esserman LJ
    Cancer Res Commun; 2022 Dec; 2(12):1579-1589. PubMed ID: 36970720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ductal Carcinoma In Situ - Quo Vadis?
    Peltecu G
    Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer--results from the GeparQuattro study (GBG 40).
    von Minckwitz G; Darb-Esfahani S; Loibl S; Huober J; Tesch H; Solbach C; Holms F; Eidtmann H; Dietrich K; Just M; Clemens MR; Hanusch C; Schrader I; Henschen S; Hoffmann G; Tiemann K; Diebold K; Untch M; Denkert C
    Breast Cancer Res Treat; 2012 Apr; 132(3):863-70. PubMed ID: 21667238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging Features of Patients Undergoing Active Surveillance for Ductal Carcinoma in Situ.
    Grimm LJ; Ghate SV; Hwang ES; Soo MS
    Acad Radiol; 2017 Nov; 24(11):1364-1371. PubMed ID: 28705686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of ductal carcinoma in situ on the outcome of invasive breast cancer. A prospective cohort study.
    Lopez Gordo S; Blanch Falp J; Lopez-Gordo E; Just Roig E; Encinas Mendez J; Seco Calvo J
    Int J Surg; 2019 Mar; 63():98-106. PubMed ID: 30738200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
    Yang M; Xu SP; Ao QL
    Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
    Tanaka K; Masuda N; Hayashi N; Sagara Y; Hara F; Kadoya T; Matsui A; Miyazaki C; Shien T; Tokunaga E; Hayashi T; Niikura N; Maeda S; Komoike Y; Bando H; Kanbayashi C; Iwata H
    Breast Cancer; 2021 Jul; 28(4):896-903. PubMed ID: 33599914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
    Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is breast magnetic resonance imaging (MRI) useful for diagnosis of additional sites of disease in patients recently diagnosed with pure ductal carcinoma in situ (DCIS)?
    Benveniste AP; Ortiz-Perez T; Ebuoma LO; Sepulveda KA; Severs FJ; Roark A; Wang T; Sedgwick EL
    Eur J Radiol; 2017 Nov; 96():74-79. PubMed ID: 29103479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component.
    Zeng Y; Gao W; Chen X; Shen K
    Br J Cancer; 2021 Mar; 124(5):975-981. PubMed ID: 33335279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is there a low-grade precursor pathway in breast cancer?
    King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
    Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coexisting ductal carcinoma in situ independently predicts lower tumor aggressiveness in node-positive luminal breast cancer.
    Wong H; Lau S; Leung R; Chiu J; Cheung P; Wong TT; Liang R; Epstein RJ; Yau T
    Med Oncol; 2012 Sep; 29(3):1536-42. PubMed ID: 21983862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
    Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
    Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positive enhancement integral values in dynamic contrast enhanced magnetic resonance imaging of breast carcinoma: ductal carcinoma in situ vs. invasive ductal carcinoma.
    Nadrljanski M; Maksimović R; Plešinac-Karapandžić V; Nikitović M; Marković-Vasiljković B; Milošević Z
    Eur J Radiol; 2014 Aug; 83(8):1363-7. PubMed ID: 24894697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of breast MRI in women eligible for breast conservation surgery and intra-operative radiation therapy.
    Paudel N; Bethke KP; Wang LC; Strauss JB; Hayes JP; Donnelly ED
    Surg Oncol; 2018 Mar; 27(1):95-99. PubMed ID: 29549911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recognizing breast ductal carcinoma in situ on fine-needle aspiration: a diagnostic dilemma.
    Guo HQ; Zhang ZH; Zhao H; Zhao LL; Pan QJ
    Diagn Cytopathol; 2013 Aug; 41(8):710-5. PubMed ID: 23729369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor.
    Kim JY; Han W; Moon HG; Park IA; Ahn SK; Kim J; Lee JW; Kim T; Kim MK; Noh DY
    Clin Breast Cancer; 2013 Oct; 13(5):385-91. PubMed ID: 23870857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?
    Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares Á; Vázquez-Caruncho M
    Eur Radiol; 2020 Jan; 30(1):514-522. PubMed ID: 31375867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the correlation between FDG PET findings of IDC breast carcinoma and histopathology of coexisting ductal carcinoma in-situ.
    Sarikaya I; Sarikaya A; Albatineh AN; Tastekin E; Sezer YA
    Nucl Med Rev Cent East Eur; 2022; 25(1):6-11. PubMed ID: 35137931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the association of mammographic density and clinical factors with ductal carcinoma in situ versus invasive ductal breast cancer in Korean women.
    Ko H; Shin J; Lee JE; Nam SJ; Nguyen TL; Hopper JL; Song YM
    BMC Cancer; 2017 Dec; 17(1):821. PubMed ID: 29207971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.